LncRNA IGFBP7-AS1 facilitates gastric cancer cell aggressiveness and is associated with poor prognosis via miR-216a-5p-mediated NF-κB activation

Objective This study aimed to elucidate the clinical significance and molecular mechanisms of lncRNA IGFBP7-AS1 in gastric cancer progression. Methods IGFBP7-AS1 expression levels were examined using the GSE174237 dataset, followed by validation in 115 pairs of gastric cancer specimens and their corresponding non-cancerous counterparts. Kaplan-Meier and Cox regression analyses were employed to evaluate its prognostic significance. Functional experiments were conducted in gastric cancer cell lines. The interaction between IGFBP7-AS1 and miR-216a-5p was confirmed, and the activation status of the NF-κB signaling cascade was examined. Results IGFBP7-AS1 transcript levels were markedly elevated in both gastric cancer specimens and cell lines relative to controls. Upregulation of IGFBP7-AS1 positively correlated with lymph node involvement ( P = 0.016), disease stage advancement (III–IV, P = 0.006), and diminished overall survival ( P < 0.001), with multivariate analysis showing that high IGFBP7-AS1 expression was independently associated with adverse outcomes in this cohort ( P = 0.002). Additionally, IGFBP7-AS1 silencing substantially impaired gastric cancer cell growth, motility, and tissue invasiveness. IGFBP7-AS1 was found to negatively associate with miR-216a-5p. Rescue experiments demonstrated that knockdown of IGFBP7-AS1 led to reduced phosphorylation ratios of p65, IκBα, and IKKβ, whereas co-inhibition of miR-216a-5p partially restored these phosphorylation levels. Conclusions IGFBP7-AS1 was associated with shorter overall survival in our cohort and promotes gastric cancer progression at least in part by sponging miR-216a-5p and activating the NF-κB signaling pathway. These findings suggest IGFBP7-AS1 as a potential prognostic biomarker and a possible therapeutic target, but its clinical utility requires further validation in a larger, multicenter, prospective cohort.

Authors

Publication Details

Journal
Hereditas
Published
2026-11-19
DOI
https://doi.org/10.1186/s41065-026-00764-w
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

LncRNA IGFBP7-AS1 facilitates gastric cancer cell aggressiveness and is associated with poor prognosis via miR-216a-5p-mediated NF-κB activation

Zheng He, Zhisheng Xia, Junxiong Deng, Guanhui He et al.
Hereditas
Cancer-related molecular mechanisms research
article

LncRNA IGFBP7-AS1 facilitates gastric cancer cell aggressiveness and is associated with poor prognosis via miR-216a-5p-mediated NF-κB activation

Zheng He, Zhisheng Xia, Junxiong Deng, Guanhui He, Huiling Qin, Keyu Zhou, Meng Tian
article en

Abstract

Objective This study aimed to elucidate the clinical significance and molecular mechanisms of lncRNA IGFBP7-AS1 in gastric cancer progression. Methods IGFBP7-AS1 expression levels were examined using the GSE174237 dataset, followed by validation in 115 pairs of gastric cancer specimens and their corresponding non-cancerous counterparts. Kaplan-Meier and Cox regression analyses were employed to evaluate its prognostic significance. Functional experiments were conducted in gastric cancer cell lines. The interaction between IGFBP7-AS1 and miR-216a-5p was confirmed, and the activation status of the NF-κB signaling cascade was examined. Results IGFBP7-AS1 transcript levels were markedly elevated in both gastric cancer specimens and cell lines relative to controls. Upregulation of IGFBP7-AS1 positively correlated with lymph node involvement ( P = 0.016), disease stage advancement (III–IV, P = 0.006), and diminished overall survival ( P < 0.001), with multivariate analysis showing that high IGFBP7-AS1 expression was independently associated with adverse outcomes in this cohort ( P = 0.002). Additionally, IGFBP7-AS1 silencing substantially impaired gastric cancer cell growth, motility, and tissue invasiveness. IGFBP7-AS1 was found to negatively associate with miR-216a-5p. Rescue experiments demonstrated that knockdown of IGFBP7-AS1 led to reduced phosphorylation ratios of p65, IκBα, and IKKβ, whereas co-inhibition of miR-216a-5p partially restored these phosphorylation levels. Conclusions IGFBP7-AS1 was associated with shorter overall survival in our cohort and promotes gastric cancer progression at least in part by sponging miR-216a-5p and activating the NF-κB signaling pathway. These findings suggest IGFBP7-AS1 as a potential prognostic biomarker and a possible therapeutic target, but its clinical utility requires further validation in a larger, multicenter, prospective cohort.

Hereditas
Cancer-related molecular mechanisms research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon